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The Journal of Immunology
Bioluminescent Reporting of In Vivo IFN-g Immune
Responses during Infection and Autoimmunity
Catherine J. Reynolds,* Deborah L. W. Chong,* Yihan Li,* S. Lucas Black,*
Amy Cutler,† Zoe Webster,† Jiten Manji,* Daniel M. Altmann,* and Rosemary J. Boyton*
IFN-g is a key cytokine of innate and adaptive immunity. It is important to understand temporal changes in IFN-g production and
how these changes relate to the role of IFN-g in diverse models of infectious and autoimmune disease, making the ability to
monitor and track IFN-g production in vivo of a substantial benefit. IFN-g ELISPOTs have been a central methodology to
measure T cell immunity for many years. In this study, we add the capacity to analyze IFN-g responses with high sensitivity and
specificity, longitudinally, in vitro and in vivo. This allows the refinement of experimental protocols because immunity can be
tracked in real-time through a longitudinal approach. We have generated a novel murine IFN-g reporter transgenic model that
allows IFN-g production to be visualized and quantified in vitro and in vivo as bioluminescence using an imaging system. At
baseline, in the absence of an inflammatory stimulus, IFN-g signal from lymphoid tissue is detectable in vivo. Reporter transgenics
are used in this study to track the IFN-g response to Pseudomonas aeruginosa infection in the lung over time in vivo. The
longitudinal development of the adaptive T cell immunity following immunization with Ag is identified from day 7 in vivo. Finally,
we show that we are able to use this reporter transgenic to follow the onset of autoimmune T cell activation after regulatory T cell
depletion in an established model of systemic autoimmunity. This IFN-g reporter transgenic, termed “Gammaglow,” offers a
valuable new modality for tracking IFN-g immunity, noninvasively and longitudinally over time. The Journal of Immunology,
2019, 202: 2502–2510.
T
here has been a strong impetus to generate transgenic
mouse strains able to facilitate imaging of adaptive
immune responses. This has led to the use of new,
transgenic, mouse reporter strains for several cytokines as well
as for NF-kB as a marker of transcriptional activation of innate
and adaptive immunity. With the exception of bioluminescent
reporter NF-kB reporter mice for biophotonic imaging, the
majority of strains use fluorescent reporters for two-photon
imaging modalities. We set out in this study to generate a re-
porter strain for in vivo screening of the immune responses
involving IFN-g as an effector cytokine.
IFN-g is produced by activated lymphocytes, including NK
cells, NKT cells, CD4+, and CD8+ T cells (1), although IFN-g
production by other leukocytes, such as monocytes/macrophages
(2), dendritic cells (3) and neutrophils (4), has been described.
Increased susceptibility to infection as a consequence of defective
expression of IFN-g or its receptor in both mice (5) and humans
(6, 7) highlights a central role for IFN-g in both viral and bacterial
pathogen clearance. Conversely, overexpression of this cytokine
has been associated with aberrant inflammation and autoimmunity
(8, 9). However, there are many examples of anti-inflammatory
actions ascribed to IFN-g (10), so that the resulting picture is a
nuanced one in which the role of IFN-g is highly context and
timing dependent (11).
The ability to monitor IFN-g production, noninvasively, in an
in vivo setting, over extended periods of time would be of
enormous value in the study of diverse disease models of in-
fection, tumor immunity, and autoimmunity. Such a modality
offers the potential for real-time, noninvasive monitoring of Th1
adaptive immunity.
Many cytokine reporter mice have been generated, the majority
of which function by expressing a fluorescent marker under the
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control of the cytokine gene promoter (12). YETI and GREAT
mice are examples of IFN-g reporters wherein IFN-g production
can be imaged through yellow fluorescent protein expression (13,
14). In both of these lines, the fluorescent marker is targeted to the
endogenous IFN-g locus as a knock-in. An alternative approach
employed in some transgenic reporter lines, including an IFN-g
reporter in which IFN-g+ cells are tagged as Thy1.1+ (15), is to
use a bacterial artificial chromosome (BAC) transgene. A BAC
transgenic approach means that it is possible to use extensive,
endogenous promoter and enhancer elements to faithfully report
expression patterns from the gene locus of interest.
Cytokine reporter mice generated to date are not suited to in vivo
bioluminescence reporting of IFN-g immunity. Common approaches
for in vivo imaging studies use bioluminescent molecules and their
substrates, such as firefly, Renilla, and bacterial luciferases (16).
Bioluminescent reporter systems have previously been developed for
some other cytokines, such as IL-7 (17) and IFN-b (18). Further-
more, NF-kB/luciferase reporter mice have been invaluable for ge-
neric imaging of inflammatory responses and their regulation.
Although these mice are valuable for tracking innate immunity or
inflammation, none allows the capacity to track type 1 immunity
in vivo; a vast array of immunology applications depends on the
ability to track IFN-g responses, be these to virus, bacteria, tumor,
fungi, or autoimmunity. Our specific intention was to make this
achievable allowing the noninvasive, longitudinal analysis of
IFN-g responses from the earliest stage.
In this study, we report the generation of an IFN-g reporter mouse in
which IFN-g production can be visualized in vivo as a bioluminescent
signal from firefly luciferase. We show that IFN-g is continuously
produced by lymphoid tissue at steady-state and that this model can be
used to study IFN-g production during longitudinal infection studies, to
monitor primary immune responses to Ag, and to track the onset of
inflammation and tissue infiltration during systemic autoimmunity.
Materials and Methods
Modification of IFN-g BAC clone
BAC clone RP24-368M14 (bacpacresources.org) was modified to replace
exons 1–4 of the ifng gene with a reporter construct containing coding
sequences for the firefly luciferase gene, luc2 (from imaging vector pGL2;
Promega), GFP, a bovine growth hormone polyadenylation signal (PolyA),
and a kanamycin resistance gene (KanR) (Fig. 1A). Correct targeting to the
ifng gene was achieved using a 93-bp 59 homology arm and a 163-bp 39
homology arm immediately upstream of ifng exon 1 and downstream of
ifng exon 4, respectively. The BAC clone was modified using the Red/ET
recombination method and linearized using PI-SceI prior to pronuclear
injection into C57BL/6 3 CBA oocytes.
Genotyping of IFN-g reporter transgenics
Mice were genotyped by PCR using genomic DNA isolated from ear
biopsy specimens. IFN-g reporter mice were identified by the presence
of a 300-bp PCR product using primers specific for the luc2 gene (for-
ward primer: 59-ACAAGTACGACCTGAGCAAC-39; reverse primer: 59-
CTGGTAGCCCTTGTACTTGAT-39).
Mice
Transgenic mouse generation, breeding, and experiments were performed
within U.K. Home Office legislation under the terms of a project license
(Public Project License No. 70/7708) granted for this work under the
“Animals (Scientific Procedures) Act 1986.” The founder IFN-g reporter
mouse was crossed onto the C57BL/6 strain to establish the transgenic
line. Reporter mice were crossed with Foxp3-DTR–inducible knockout
mice (19) to allow regulatory T cell (Treg) depletion experiments. The
mice were then bred to homozygosity for the reporter construct.
In vivo and in vitro bioluminescence imaging
Mice were injected i.p. with 150 mg/kg XenoLight D-luciferin – K+ Salt
(PerkinElmer, U.K.). Mice were left for 10 min prior to the induction of
anesthesia using isoflurane and bioluminescence measurement using an
IVIS Lumina II Imaging System (PerkinElmer). Average radiance for areas
of interest in bioluminescence images were calculated using Living Image
4.2 Software (PerkinElmer). For an in vitro measurement of biolumines-
cence using cultured cells, cells were transferred to black 96-well tissue
culture plates before the addition of D-luciferin at a final concentration of
150 mg/ml. Cells were incubated for 10 min before imaging.
In vitro cell culture
Single-cell suspensions of splenocytes from IFN-g reporter or nontransgenic
mice were cultured in RPMI medium containing 10% FCS and 50 mM 2-ME
and supplemented with L-glutamine and penicillin–streptomycin. For stim-
ulations with PMA and ionomycin, cells were cultured for 24 h with a 2-fold
dilution series starting at 50 ng/ml PMA and 1 mg/ml ionomycin. For po-
larization experiments, cells were stimulated with anti-CD3 (1 mg/ml) and
anti-CD28 (0.5 mg/ml) (eBioscience), with the addition of rIL-2 (10 IU/ml)
and rIL-12 (10 ng/ml) for Th1-polarizing conditions and rIL-2 (10 IU/ml),
rIL-4 (10 ng/ml), and anti–IFN-g (10 mg/ml) for Th2-polarizing conditions.
All recombinant cytokines were purchased from R&D Systems. Anti–IFN-g
was purchased from Life Technologies.
Quantification of IFN-g by ELISA and real-time PCR
IFN-g in cell culture supernatants or in homogenized lung tissue was
quantified by ELISA, using paired Abs specific for mIFN-g (Mabtech).
Lung tissue samples were prepared by homogenizing the lung at a con-
centration of 100 mg/ml in Hank’s balanced salt solution, without MgCl2
or CaCl2, containing a protease inhibitor mixture (Roche). For quantifi-
cation of ifng transcripts by real-time PCR, RNA was isolated from the
lung tissue using TRIzol (Life Technologies) and reverse transcribed using
SuperScript III (Life Technologies). Real-time PCR reactions were per-
formed using Brilliant II QPCR Low ROX Master Mix (Applied Biosystems)
with gapdh and ifng gene-specific primers and probes (Assays-on-Demand
Gene Expression assays; Applied Biosystems).
Pseudomonas aeruginosa lung infection
P. aeruginosa, strain PA01, was grown in Luria–Bertani broth overnight at
37˚C. Mice were anesthetized with isoflurane and infected intranasally
with 5 3 106 CFU in sterile PBS. At the point of cull, lung tissue from
each mouse was harvested for CFU determination by the plating of ho-
mogenized lung samples onto Luria–Bertani agar and colony counting.
Immunization with Pseudomonas OprF Ag
Mice were immunized s.c. in one hind footpad with 1, 5, or 25 mg of rOprF
protein (20) emulsified with Hunter “TiterMax Gold” adjuvant (Sigma-Aldrich)
or with adjuvant emulsified with PBS alone. At 11 d postimmunization, the
draining popliteal lymph nodes were harvested and disaggregated into a single-
cell suspension. CD4+ T cells responding to OprFAg were quantified by IFN-g
ELISPOT (Diaclone; 2BScientific) performed in HL-1 serum-free medium
(BioWhittaker) supplemented with L-glutamine and penicillin–streptomycin.
Cells (23 105) plus Ag were added to wells of precoated anti–IFN-g ELISPOT
plates and incubated for 72 h at 37˚C with 5% CO2. Plates were developed
according to the manufacturer’s instructions, and spots were counted on an
automated ELISPOT reader (Autoimmun Diagnostika). Replica stimulations
were set up in normal tissue culture plates for the measurement of IFN-g in
culture supernatants by ELISA.
Treg depletion
Tregs in IFN-g reporter mice that had been crossed onto the Foxp3-DTR
transgenic line were depleted by either daily or alternate daily adminis-
tration (i.p.) of diphtheria toxin (DT) (1.25 mg/kg) (Sigma-Aldrich).
Results
Generation of IFN-g reporter transgenics
We set out to generate a new transgenic mouse model in which the
expression of IFN-g was reportable as a bioluminescent signal.
A BAC clone containing regulatory and coding elements of the
mouse ifng gene was modified such that all four exons of ifng were
replaced with the coding sequence of the firefly luciferase gene
(luc2), GFP, and a PolyA (Fig. 1A). Ifng is located on mouse
chromosome 10 and is the only gene in the surrounding region;
other nearby coding regions are located 145 Kb upstream (Iltifb)
and 412 Kb downstream (Dyrk2) of the ifng sequence; however,
the selected BAC clone (RP24-368M14) is 174 kb in size and does
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not contain either of these genes. As the entire coding region of
ifng had been replaced and no other coding regions are present, we
anticipated no extraneous biological consequence of expressing
the BAC construct, other than the normal positional risk of
transgene integration. The modified BAC clone was linearized and
injected into C57BL/6 3 CBA oocytes to generate an IFN-g re-
porter founder mouse. The founder IFN-g reporter mouse was
identified by PCR and crossed onto the C57BL/6 strain to estab-
lish the transgenic line.
Detection of bioluminescent signal at baseline in
reporter transgenics
To determine whether a bioluminescence signal was detectable in vivo
in healthy mice, IFN-g reporter mice and control nontransgenic mice
were injected with D-luciferin substrate, anesthetized, and imaged
using the IVIS Lumina II Imaging System. Reporter mice showed a
bioluminescent signal reproducibly detectable in the neck region
(Fig. 1B). To determine which internal organs the signal derived
from, organs were dissected and imaged ex vivo (Fig. 1C). Quanti-
fication of bioluminescence from each organ showed that the signal
predominantly derives from lymphoid tissue (spleen, lymph node,
and thymus), although a low level of bioluminescence was also de-
tectable in other tissues, including the lung and the digestive tract
(Fig. 1D). We therefore conclude that the neck signal present in
in vivo images of healthy adult mice derived from lymph nodes in
this region and that the signal from the thoracic cavity likely derived
from the thymus. The signal localized to spleen was detected ex vivo
but not in vivo, suggesting that a beneficial additional gain in sensi-
tivity may be achieved by crossing to an albino strain. Splenocytes
were analyzed by flow cytometry for expression of GFP, but this
was not detectable.
Bioluminescence signal in IFN-g reporter transgenics is linked
to IFN-g production
Data presented in Fig. 1 suggest that IFN-g is continuously
produced in the lymphoid tissue of normal, healthy mice. We
next sought to establish that the bioluminescence signal being
detected was indeed reporting IFN-g production. Splenocytes
from IFN-g reporter and nontransgenic control mice were
stimulated for 24 h with increasing doses of PMA/ionomycin to
induce T cell activation and IFN-g production. The biolumi-
nescence signal from the activated splenocytes was measured by
IVIS (Fig. 2A, 2B) and shows that there is a steady increase in
bioluminescence signal with increasing concentrations of PMA/
ionomycin. This mirrors the steady increase in IFN-g protein
secreted by activated splenocytes (Fig. 2C). In addition, actively
polarizing splenic T cells toward a Th1 or a Th2 phenotype by
stimulation in the presence of polarizing cytokines and Abs
resulted in increased and decreased bioluminescence under Th1-
and Th2-polarizing conditions, respectively (Fig. 2D, 2E). Again,
FIGURE 1. IFN-g reporter transgenic generated using
a modified BAC clone. (A) The BAC clone RP24-368M14,
containing the coding and promoter elements of the ifng
gene, was modified such that exons 1–4 of the ifng gene
were replaced with a reporter construct encoding the firefly
luciferase gene (luc2), GFP, and a PolyA. (B) IFN-g re-
porter (n = 5) and nontransgenic mice were injected i.p.
with 150 mg/kg D-Luciferin XenoLight D-luciferin – K+
Salt (PerkinElmer). Ten minutes postinjection, the biolu-
minescence signal in each mouse was detected using the
IVIS imaging system. (C) Submanibular lymph nodes
(a), salivary gland (b), thymus (c), lung (d), heart (e), skin
(f), spleen (g), kidney (h), pancreas (i), small intestine (j),
colon (k), liver (l), stomach (m), brain (n), and thyroid (o)
were removed and IVIS imaged. (D) The bioluminescence
signal was quantified by calculating the average radiance
of each organ. Error bars represent mean 6 SEM. This
experiment was repeated on two separate occasions.
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this pattern of bioluminescence mirrored the expected differ-
ences in IFN-g protein production by these different cell pop-
ulations (Fig. 2F).
IFN-g reporter transgenics can be used to monitor IFN-g
responses to infection in vivo
Having established that bioluminescence in this model faithfully
reports IFN-g production and demonstrating that the biolumines-
cent signal from internal organs is capable of penetrating tissue for
detection during in vivo imaging of a live animal, we next in-
vestigated whether this model could be used to follow the IFN-g
response to infection. We used a P. aeruginosa model of lung
infection wherein mice were infected intranasally with a nonlethal
dose and then monitored over the course of 7 d for changes in
bioluminescent signal from the thorax (Fig. 3A, 3B). Biolumi-
nescence decreased over the first 6 h of infection, peaked at day 5,
and returned to baseline by day 7. This was in the context of mice
having completely cleared the infection by this time point
(Fig. 3C). To determine whether these changes in bioluminescence
were a true reflection of the IFN-g response in this model, cohorts
of mice were culled at each time point, and lung tissue was har-
vested for IFN-g measurement at the protein and transcriptional
level. Bioluminescence correlated well with IFN-g protein mea-
surements, which also showed an initial decrease followed by a
peak at day 5 (Fig. 3D, 3F). Ifng transcripts peaked at 2 h post-
infection and decreased thereafter (Fig. 3E). These data further
validate the reporter model. Correct targeting to the ifng gene in
this reporter transgenic was achieved using a 93-bp 59 homology
arm and a 163-bp 39 homology arm immediately upstream of ifng
exon 1 and downstream of ifng exon 4, respectively. Thus we used
extensive IFN-g upstream and downstream regulatory sequence in
a 174 kb BAC clone. As such, the expression faithfully mimics IFN-g
transcription. The fact that protein expression is to some degree more
in step with bioluminescence than gene expression likely reflects
specific nuances of the stability of the IFN-g message.
IFN-g reporter transgenics for monitoring adaptive immunity
IFN-g production ex vivo is often used as a readout for recall
responses to Ag in models of infection and immunization. How-
ever, it is difficult to measure IFN-g responses occurring in vivo at
the point of the initial primary immune response to Ag. We used
IFN-g reporter mice to follow the primary IFN-g immune re-
sponse to different doses of the P. aeruginosa Ag, OprF, given
with adjuvant. Mice were immunized in the footpad, and the
bioluminescence signal was monitored over the course of 11 d of
the primary immune response (Fig. 4A, 4B); the T cell response in
this context is initially localized to the popliteal lymph node. Mice
that received adjuvant alone mounted a small IFN-g response that
increased steadily to day 7 before plateauing. The biolumines-
cence signal in these mice was indistinguishable from that in mice
that had been primed with 1 mg OprF. However, it was possible to
distinguish between mice that had received 25 or 5 mg of Ag. By
day 7, the IFN-g response in the footpad of mice that had received
25 mg OprF was significantly higher than in the other groups, and
by day 9, those mice primed with 5 mg of protein also showed a
higher bioluminescence signal than those primed with the lowest
dose or adjuvant alone. These data contrasted with that seen for
recall response to Ag, measured using draining lymph nodes
(DLN) at day 11 postimmunization by IFN-g ELISPOT and
ELISA (Fig. 4C, 4D). By IFN-g ELISPOT, all three priming doses
of Ag gave a significantly higher IFN-g signal than adjuvant alone
and were equivalent to each other in the magnitude of their IFN-g
response. Bioluminescence picks up the adaptive recall immune
response to Ag with similar sensitivity and reproducibility to the
ELISPOT at priming doses of 5 and 25 mg of Ag (Fig. 4B, 4C),
notwithstanding the caveat that bioluminescence can be assessed
daily through the study (the advantage of this approach), with
differences being identified at earlier time points, whereas the
ELISPOT is conducted as a terminal one-off analysis at day 11.
In vivo visualization of T cell activation and tissue infiltration
using IFN-g reporter transgenics
The Foxp3-DTR model of conditional Treg depletion (19) is a
well-characterized one in which loss of Tregs allows the activation
of autoimmune T cells, leading to infiltration of many different
organs and causing premature death. We crossed these mice onto
the IFN-g reporter line to determine whether the luciferase reporter
FIGURE 2. Bioluminescence signal in IFN-g reporter transgenic is
linked to IFN-g production. (A) Splenocytes from IFN-g reporter (n = 8)
and nontransgenic (n = 8) mice were stimulated with increasing doses of
PMA and ionomycin for 24 h. A concentration value of 1 represents 50 ng/ml
of PMA and 1 mg/ml Ionomycin. D-Luciferin was added to wells of the
culture plate at a concentration of 150 mg/ml and imaged for biolumi-
nescence. A representative image of the PMA and ionomycin dose re-
sponse for an IFN-g reporter and non-transgenic mouse is shown. (B)
Average radiance for each dose of PMA and ionomycin in both IFN-g
reporter (squares) and non-transgenic (circles) cell cultures were calcu-
lated. (C) Cell culture supernatants were also removed for quantification of
IFN-g protein by ELISA. (D) Splenocytes from IFN-g reporter mice (n = 6)
were stimulated with anti-CD3 and anti-CD28 Abs and cultured with or
without Th1- or Th2-polarizing cytokines for 72 h before bioluminescence
imaging. A representative image of unpolarized, Th1-polarized, and Th2-
polarized splenocytes is shown. (E) The average radiance for each culture
condition was measured, and (F) IFN-g protein levels in the culture super-
natants were determined by ELISA. Error bars represent mean6 SEM. This
experiment was repeated on two separate occasions. Statistical significance
was determined using an unpaired t test. **p , 0.005, ****p , 0.0001.
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could be used to follow the time course for the onset and lo-
cation of disease in these animals. Tregs were depleted in one
cohort of mice by the administration of DT. The increase in
bioluminescence over time in these mice was followed by IVIS
imaging (Fig. 5A) until the experimental endpoint at day 7
(Fig. 5B). The anatomical regions of the neck, thorax, and
abdomen showed bioluminescence that increased signifi-
cantly, and radiance from these areas was quantified over time
(Fig. 5C–E). The data shows that the IFN-g signal increases
following Treg depletion. At the end of the experiment, internal
organs were dissected and imaged ex vivo by IVIS (Fig. 5F).
Quantification of the bioluminescent signal from each organ
showed that increased IFN-g production was greatest in lym-
phoid organs, the digestive tract, and the pancreas but that there
was a significant increase in almost every organ analyzed
(Fig. 5F–H). This suggests that it would be possible to use this
reporter mouse to study disease development in almost any
model of autoimmune disease.
FIGURE 3. Reporter transgenic can be used to monitor IFN-g responses in vivo in a model of P. aeruginosa lung infection. IFN-g reporter mice were
infected intranasally with 5 3 106 CFU of P. aeruginosa (PA01). Mice were IVIS imaged at 0, 2, 6, 24, 120, and 168 h postinfection. (A) Representative
images at 0, 6, and 120 h postinfection are shown. (B) At each time point, average radiance of the thorax of each mouse was measured, and a cohort of mice
(n = 4) were culled for (C) determination of lung CFU burden, (D) lung IFN-g protein quantification by ELISA, and (E) relative expression of ifng
transcripts by real-time PCR. (F) Average radiance of the thorax was shown to correlate with amount of lung IFN-g protein using the Pearson product-
moment correlation coefficient. Error bars represent mean6 SEM. Statistical significance was determined using an unpaired t test. *p, 0.05, **p, 0.005,
***p , 0.0005.
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FIGURE 4. The adaptive T cell IFN-g response to different priming doses of Ag can be detected by IVIS imaging in reporter transgenics. (A) IFN-g
reporter mice were immunized s.c. in the footpad with 25 mg (n = 9), 5 mg (n = 8), or 1 mg (n = 9) of the P. aeruginosa Ag OprF in TiterMax adjuvant or
with TiterMax adjuvant alone (n = 7). A representative image for each group at day 9 postimmunization is shown. (B) Bioluminescence signal from the
immunized footpad of each mouse was quantified on days 0, 1, 2, 3, 4, 7, 9, and 11. Data are from two independent experiments combined. (C) At day 11
postimmunization, DLN cells were harvested from mice that had been immunized with TiterMax only (circles) or 25 mg (squares), 5 mg (triangles), or 1 mg
(diamonds) of OprF protein and assayed for IFN-g production in response to different doses of OprF by ELISPOT and by (D) ELISA, using supernatants
from DLN cells cultured with OprF protein for 3 d. Error bars represent mean 6 SEM. For bioluminescence data, statistical significance between mice
primed with Ag and those primed with adjuvant only was determined using an unpaired t test. *p , 0.05.
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FIGURE 5. T cell activation and tissue infiltration in the Foxp3-DTR model can be tracked and visualized using the IFN-g reporter transgenics.
IFN-g reporter mice that had been crossed onto the Foxp3-DTR transgenic line (n = 6) were given DT (1.25 mg/kg) on alternate days via i.p. injection.
Another cohort of mice did not receive any DT (n = 6). Mice were IVIS imaged. (A) Representative images of untreated and DT-treated mice on days
0, 1, 2, 3, and 6 are shown. (B) Representative images of untreated and DT-treated mice at the end of the experiment (day 7) are shown. Average
radiance of the neck (C), thorax (D), and abdominal (E) regions of each untreated (circles) and DT-treated (squares) mouse were measured. (F) All mice
were culled at day 7, and submandibular lymph nodes (a), salivary gland (b), thymus (c), lung (d), heart (e), skin (f), spleen (g), kidney (h), pancreas
(i), small intestine (j), colon (k), liver (l), stomach (m), brain (n), and adrenal glands (o) were dissected and IVIS imaged. Average radiance was
calculated for (G) lymphoid tissue and (H) all other organs in untreated (white bars) and DT-treated (black bars) mice. Data shown are mean 6 SEM.
This experiment was repeated on two separate occasions. Statistical significance between DT-treated and untreated mice was determined using an
unpaired t test. *p , 0.05, **p , 0.005, ***p , 0.0005, ****p , 0.0001.
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Discussion
During recent decades of research into T cell immunology in mouse
models, a range of approaches have been developed to quantify
Ag-specific immunity. The field has witnessed the progression
through preference for measuring delayed hypersensitivity by
tissue thickening and then [3H]thymidine incorporation assays,
ELISPOTs, intracellular cytokine staining, and CFSE dilution.
Our aim in this study was to add to this arsenal an in vivo, non-
invasive assay that would offer a sensitive readout of adaptive,
Th1 immunity in real time in live mice. The application of a
bioluminescent reporter for cytokine promoter activation affords
the potential for in vivo imaging across a time course using a
simple IVIS chamber. This offers clear advantages in terms of ease
of immune assays and also has important implications for animal
welfare with reduced mouse numbers being used because the same
immunized cohort can be followed and imaged longitudinally.
Bioluminescent imaging of IFN-g offers an approach to questions
of comparative screening of T cell immune responses, whether
comparing between vaccines, Ags, adjuvants, or inhibitory ther-
apeutics. As an easily understandable shorthand, we have termed
this reporter strain “Gammaglow.”
In the current study, we generated a construct based on a BAC
carrying the murine ifng locus, but the approach can readily be
adapted to any other cytokine. An obvious approach might be
to generate the resource of a series of cytokine reporters encom-
passing IL-4, IL-17, and IL-10 and carrying bioluminescent reporters
emitting at nonoverlapping wavelengths. Although the BAC construct
generated for this work yielded a strong luciferase signal, the corre-
sponding enhanced GFP signal was poor, making it impossible, for
example, to phenotype and sort responding cells by flow cytometry. It
will be necessary in the future to look at exchanging the enhanced
GFP cassette for an alternative fluorescent protein. Furthermore, al-
though the signal from lymphoid organs was sufficient for IVIS
imaging in vivo for our studies, the use of these mice would be further
enhanced by crossing onto an albino background.
During initial characterization of the reporter line, it was noted
that at baseline, housed in a specific pathogen-free facility, trans-
genics showed a significant IFN-g signal from spleen, submandib-
ular lymph nodes, thymus, and lung (Fig. 1). Further studies will be
needed to determine the cellular origins and driver of this IFN-g
responsiveness; this may constitute an ongoing, homeostatic re-
sponse to environmental or microbiota antigenic stimulation. An
interesting finding from the P. aeruginosa infection studies was that
there was an initial drop in this baseline IFN-g signal. This observed
reduction in background IFN-g signal may be because of reduced
drive from the lung microbiota because of competition for the
lung niche.
In initial studies to validate the bona fides of the Gammaglow
reporter mice for reporting IFN-g responsiveness, we compared
PMA/ionomycin in vitro stimulation of splenocytes in terms of bio-
luminescence relative to actual IFN-g ELISA. Detection of an IFN-g
response was more sensitive by bioluminescence than by ELISA.
An important application for cytokine bioluminescence strains
such as Gammaglow is in monitoring responses to infection, in-
cluding the efficacy of vaccine strategies. In the current study, we
demonstrate this principle through the example of lung infection
by P. aeruginosa. Vaccine studies indicate that a T cell IFN-g
response is a component of protective immunity to P. aeruginosa
(21). Noninvasive IVIS imaging detected the IFN-g response to
P. aeruginosa from ∼24 h postinfection. The novelty of these
challenge studies is thus not in the ability to study P. aeruginosa
infection per se but the capacity to identify activation of an in vivo
IFN-g response as early as 24 h postinfection, offering the facility
to monitor the response in real time from initial recognition and
cellular activation. This has important implications for assessing
correlates of protection to a pathogen of considerable current
concern with respect to antimicrobial resistance and the need
for vaccine programs. Because of the relative ease with which
extremely bright, bioluminescently labeled pathogens can be
engineered, there is clear potential in this study to combine these
approaches to allow simultaneous IVIS imaging using different
luciferases for measurements of pathogen load/spread and the
host adaptive response to it. Using Gammaglow mice to monitor
the response in vivo to footpad immunization with P. aeruginosa
Ag in adjuvant, we found that adjuvant alone elicited an IFN-g
signal, but the Ag-specific response could be detected as early
as 7 d after immunization. The TiterMax Gold adjuvant used
would indeed be expected to enhance baseline IFN-g because it
contains CRL-8300 copolymer in squalene.
A key driver for our efforts to generate bioluminescence cytokine
reporter mice has been the need for tools for the characterization of
autoimmune pathogenesis and its control. In an age of clinical trials
using anti-cytokine biologics, there has been considerable need to
appraise the differential contributions of effector cytokines to
various autoimmune pathologies in preclinical studies using mu-
rine models. Fontolizumab, a therapeutic monoclonal targeting
IFN-g, has been trialed in a number of clinical autoimmunity
settings, including phase II trials (22). Even for diseases such as
multiple sclerosis and type 1 diabetes in which attention has fo-
cused on a pathogenic role of IL-17, there is much evidence for
involvement of IFN-g+ cells (23, 24). As a means of investigating
the development of autoimmune disease in vivo, we made use of
the fact that Foxp3-DTR mice develop spontaneous, systemic,
lethal autoimmunity on depletion of Tregs by DT treatment (19).
When Kim and colleagues (19) injected mice with DT from birth
and then on alternate days, mice became moribund by day 27 with
H&E staining showing intense mononuclear infiltrates in liver,
lung; and skin. By flow cytometry, a majority of deregulated
T cells had become activated as measured, for example, by Ki-67
expression. Analysis of autoimmune etiology would be greatly
aided by the ability to track (and then characterize) the appearance
of activated, autoimmune cells at disease sites early in the process.
To investigate the feasibility of this approach, in this study, we
treated Foxp3-DTR mice with DT. By in vivo IVIS imaging, de-
regulation of an autoimmune IFN-g response was apparent as
early as day 6. Thus, in addition to the prior understanding that
Treg-deregulated mice show florid mononuclear infiltrates (by
H&E histology) in diverse organs, we were now able to show that,
starting from a strong signal in spleen, thymus, and submandibular
lymph nodes and then other sites including pancreas, ileum, colon,
heart, lung, and brain, this approach can be used to track the ap-
pearance of autoimmune IFN-g+-activated cells, which can then
be used in studies of autoimmune mechanism. Analyzing the
autoimmune response at a single, fixed endpoint of 4 wk by post
mortem H&E staining of infiltrated tissues has been the standard
in Treg depletion studies. This new model offers the significant
advance of being able to follow the kinetics of the earliest auto-
immune events, shown in this study as detectable from day 6, and
also allowing precise quantification of the autoimmune infiltration
into each organ in the face of Treg deregulation. These data have
not been readily attainable by other approaches. Using data from
IVIS tracking of autoimmunity in this new model, researchers will
be able to track and characterize the earliest events in the auto-
immunity of deregulated mice in affected organs.
In summary, using the example of Gammaglow IFN-g–BAC
luciferase reporter transgenic, we demonstrate in this study the
principle of using bioluminescence cytokine reporters as a means
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of tracking IFN-g immunity in Ag discovery as well as autoim-
mune or infectious disease settings. This offers the potential of
noninvasive, longitudinal analysis of immune responses over time
as well as identification of anatomical sites of response. Impor-
tantly, it also offers ethical advantages through substantial re-
duction in numbers. The former Editor-in-Chief of The Journal of
Immunology, Pamela Fink, added a new section to the Table of
Contents of The Journal of Immunology, called Novel Immuno-
logical Methods (25). She emphasized the need for peer review
journals to work with researchers seeking to describe, “novel re-
agents, new genetically manipulated lines of mice, and innovative
techniques in sufficient detail and with the appropriate experi-
mental validation” (25). She proposed that this section would
provide a home for such work and provide “a good resource for
those who want to apply such new technology to solve pressing
immunological issues” (25). This new approach to type 1 immunity
analysis offers just such a resource.
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